MedTrace Logo

Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High Myopia

NCT00967850 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2024-10-31

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and safety of intravitreal injections of bevacizumab in High Myopia´s choroidal neovascularization versus the standard treatment of Photodynamic therapy.

Conditions

  • Myopia
  • Choroidal Neovascularization

Interventions

DRUG

Intravitreal Injection

Intravitreal injection of 1,25 mg in 0,05 ml

DRUG

Photodynamic Therapy (Visudyne)

Photodynamic therapy on day 1 as described in standard clinical guidelines.

Sponsors & Collaborators

  • Fondo de Investigacion Sanitaria

    collaborator OTHER

  • Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA

    lead OTHER

Principal Investigators

  • José Carlos Pastor Jimeno, MD, PhD · IOBA - Instituto Universitario de Oftalmobiología Aplicada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00967850 on ClinicalTrials.gov